Simplist® Ready-to-Administer Syringes
Available exclusively from Fresenius Kabi
9 medications in 17 presentations
Simplist ready-to-administer prefilled syringes provide streamlined medication management from pharmacy to point-of-care, eliminating steps where errors can occur.
- No assembly required
- No point-of-care preparation
- Luer-Lok™ connectivity
- FDA approved, manufacturer-prepared, cGMP compliant
- 24-month shelf life
- Clear and distinct labels help differentiate Simplist product offerings
- Individually barcoded
- Large, legible type
- Easily identifiable product name and dosage
- Color differentiated labels
DILAUDID INJECTION IMPORTANT SAFETY INFORMATION
INDICATIONS AND USAGE
DILAUDID INJECTION is indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate.
Limitations of Use: Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve DILAUDID INJECTION for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: have not been tolerated, are not expected to be tolerated, have not provided adequate analgesia, or are not expected to provide adequate analgesia.
DILAUDID INJECTION is contraindicated in patients with significant respiratory depression, acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment, known or suspected gastrointestinal obstruction, known hypersensitivity to hydromorphone, hydromorphone salts, sulfite-containing medications, or any other components of the product.
Life-threatening respiratory depression in patients with chronic pulmonary disease or in elderly, cachectic, or debilitated patients: Monitor closely, particularly during initiation and titration.
Adrenal insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid.
Severe hypotension: Monitor during dosage initiation and titration. Avoid use in patients with circulatory shock.
Risks of use in patients with increased intracranial pressure, brain tumors, head injury, or impaired consciousness:
Monitor for sedation and respiratory depression. Avoid use in patients with impaired consciousness or coma.
Additional serious adverse reactions: Apnea, circulatory depression, respiratory arrest, shock, cardiac arrest, seizures, withdrawal, anaphylaxis. Most common adverse reactions: Lightheadedness, dizziness, sedation, nausea, vomiting, sweating, flushing, dysphoria, euphoria, dry mouth, and pruritus.
To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176, option 5, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
DILAUDID INJECTION contains sodium metabisulfite.
Overdosage: Acute overdose can be manifested by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, miosis (or mydriasis when hypoxia is present), and, in some cases, pulmonary edema, bradycardia, hypotension, partial or complete airway obstruction, atypical snoring, and death.
This Important Safety Information does not include all the information needed to use DILAUDID safely and effectively. Please see full prescribing information for DILAUDID INJECTION, including Boxed Warning available at www.simplist-us.com.